Barclays Lifts PT on Thermo Fisher Scientific (TMO) to $490 From $450

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the top low volatility healthcare stocks to buy now. On July 24, Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $490 from $450, keeping an Equal Weight rating on the shares.

Thermo Fisher Scientific’s (TMO) Dividend: Steady Payouts in a Growing Market

A workstation in a research lab stocked with laboratory products and services.

The analyst told investors in a research note that Thermo Fisher Scientific Inc. (NYSE:TMO) reported a Q2 beat, with Q2 revenue rising 3% to $10.85 billion. GAAP diluted earnings per share for the quarter grew 6% to $4.28, while adjusted EPS reached $5.36.

Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery.

It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments.

While we acknowledge the potential of TMO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TMO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.